Idasanutlin is an investigational drug.
There have been 15 clinical trials for Idasanutlin.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 30th 2015.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, St. Jude Children's Research Hospital, and National Cancer Institute (NCI).
There are twenty-seven US patents protecting this investigational drug and three hundred international patents.